Pragmatic, Multicenter, Double-Blind Evaluation of Circulating Cancer-Associated Macrophage-Like Cells for Detection of Cancer in Indeterminate Pulmonary Nodules.

Authors

Martin J Edelman, Anil Vachani, Dana Marie Haagen Zambino, Eric Ross, Rohit Kumar, Alan Haber, David Dibardino, Karen Ruth, Jordan Anaokar, Maruti Kumaran, Kirby P Gardner, Cha-Mei Tang, Daniel L Adams

Published in

JCO precision oncology. Volume 10. Issue 7. Pages e2501142. Epub Jul 10, 2026.

Abstract

Cancer-associated macrophage-like cells (CAMLs) are specialized myeloid polyploid cells that emanate from primary tumor masses and transit circulation in a variety of malignancies, which have the potential to track cancer progression and therapy response. Previous studies have demonstrated that larger CAMLs (≥30 μM and ≥50 μM) are particularly associated with disease progression. We hypothesized that CAMLs could provide additional cancer risk information for patients with indeterminate lung nodules.
This was a double-blind, multicenter study to evaluate CAMLs in the blood as diagnostic biomarkers for malignancy. We enrolled 203 patients with indeterminate nodules (0.8-3 cm) and no diagnosis of cancer. Blood samples were obtained at the time of the initial evaluation and before diagnostic procedures; physicians were blinded to the CAML results. We determined the prevalence of CAMLs ≥30 μM (CAML+) at the initial screening and calculated screening statistics including positive predictive value (PPV), negative predictive value (NPV), sensitivity, and specificity of CAML+ for any malignancy detected during follow-up.
Of the 203 enrolled patients, 200 had their samples sent for CAML analysis. For evaluable patients (n = 191), there were 41 with non-small cell lung cancer, four with small cell lung cancer, six with carcinoid, and five with other malignancies. For eight patients, a biopsy was either nondiagnostic or not feasible; they were treated for lung cancer with radiotherapy (and counted as cancer). CAMLs were detected in 45.0% of all patient samples (95% CI, 37.8% to 52.4%). For the detection of any malignancy, CAML PPV and NPV were 27.9% and 61.9%, respectively, and sensitivity and specificity were 37.5% and 51.2%, respectively. Defining CAML+ as larger CAML size (≥50 μM) did not significantly alter the results.
CAMLs are neither sensitive nor specific to the presence of malignancy in indeterminate pulmonary nodules.

PMID:
42430695
Bibliographic data and abstract were imported from PubMed on 11 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.